First oral antiviral for COVID-19, Lagevrio (molnupiravir), approved by MHRA
The first pill designed to treat symptomatic Covid has been approved by the UK medicines regulator.
The tablet - molnupiravir - will be given twice a day to vulnerable patients recently diagnosed with the disease.
In clinical trials the pill, originally developed to treat flu, cut the risk of hospitalisation or death by about half.
For more information, please see: https://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra